Search

Displaying results 641 - 650 of 3917 in total
  1. Drug

    Quercus alba pollen

    go.drugbank.com/drugs/DB10376
    Approved

    Quercus alba pollen, or oak white pollen, is a non-standardized allergen extract used for the diagnosis and treatment of allergic disease to grass pollen.

    Categories: Non-Standardized Pollen Allergenic Extract
  2. Drug

    Teplizumab

    go.drugbank.com/drugs/DB06606
    ApprovedInvestigational

    Teplizumab was designed as an Fc-non-binding antibody in order to reduce the incidence of CRS. … [A241480] On November 2022, teplizumab was approved by the FDA as the first drug that can delay the onset of type 1 diabetes.

  3. Drug

    Veltuzumab

    go.drugbank.com/drugs/DB05656
    Investigational

    Veltuzumab is a monoclonal antibody which, as of October 2009, is undergoing Phase I/II clinical trials for the treatment of non-Hodgkin's lymphoma.

  4. Drug

    Lemborexant

    go.drugbank.com/drugs/DB11951
    ApprovedInvestigational

    [zopiclone], [zolpidem], benzodiazepines) focus on enhancing sleep drive via modulation of GABA and melatonin receptors, lemborexant and other orexin antagonists (e.g. … [L10863] Recent research in the field of sleep disorders has revealed that insomnia is likely driven not by the inability of the brain to "switch on" sleep-related circuits, but rather an inability to

  5. Drug

    Pralidoxime

    go.drugbank.com/drugs/DB00733
    ApprovedInvestigationalVet approved

    If given within 24 hours,after organophosphate exposure, pralidoxime reactivates the enzyme cholinesterase by cleaving the phosphate-ester bond formed between the organophosphate and acetylcholinesterase

  6. Drug

    Methopterin

    go.drugbank.com/drugs/DB16620
    Investigational

    Methopterin is thought to have effects on osteoclasts and to inhibit inflammatory bone destruction.[A229843]

  7. Drug

    Pariglasgene brecaparvovec

    go.drugbank.com/drugs/DB16801
    Approved

    continued approval potentially contingent on confirmatory trials. … [L64050] The FDA granted pariglasgene brecaparvovec-opnr accelerated approval on August 19, 2026, making it the first approved treatment for glycogen storage disease type Ia.

  8. Drug

    Gadofosveset trisodium

    go.drugbank.com/drugs/DB06705
    Approved

    Gadofosveset trisodium is an intravenous contrast agent used with magnetic resonance angiography(MRA), which is a non-invasive way of imaging blood vessels.

  9. Drug

    Linvoseltamab

    go.drugbank.com/drugs/DB17447
    ApprovedInvestigational

    Linvoseltamab (INN), marketed as Lynozyfic™, is a bispecific human IgG4 monoclonal antibody developed by Regeneron that promotes the interaction of B-cell maturation antigen (BCMA) on multiple myeloma

  10. Drug

    Vecuronium

    go.drugbank.com/drugs/DB01339
    ApprovedInvestigational

    A non-depolarizing neuromuscular blocking agent with shorter duration of action than pancuronium. … Its lack of significant cardiovascular effects and lack of dependence on good kidney function for elimination as well as its short duration of action and easy reversibility provide advantages over, or